Lee et al. showed that germline BRCA1 and 2 mutation-associated ovarian cancer, which is believed to have higher response rates to platinum-based chemotherapy than BRCA wild-type [34], has fewer circulating MDSCs and higher CD8+ T cells in PBMC compared with BRCA wild-type ovarian cancer [24]. The gene discussed is CD8A; the disease is ovarian cancer.